Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy

NCT01397799 is registered in ClinicalTrials.gov with Kinex Pharmaceuticals Inc. as lead sponsor.

NCT NCT01397799
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01397799 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Rising Multiple-Dose Study to Evaluate Safety, Tolerability and Activity of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia Who Are Refractory to or Have Declined Standard Induction Therapy
Lead sponsor
Kinex Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2013
Completion date
July 31, 2014
Enrollment
24 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute myelogenous leukemia